Contribution: Industrial Research Assistance Program – Contributions to Firms
Tieos Pharmaceuticals Inc.
$50,000.00
Cell Line Testing for Tumor Shrinkage
FY 2018-19 · 2018-06-04
Summary
Tieös Pharmaceuticals is a pre-clinical stage biotech company with the goal of creating novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells.
With the use of advanced AI-based computational biology and 3D in-silico models, we have developed lead polypharmocological compounds which will each target multiple metabolic pathways simultaneously; creating synergies and reducing toxicity. Through a proprietary weighting of cancer specific metabolic pathways, we have now synthesized our five lead compounds and are conducting proof-of-concept in-vitro testing.
At Tieös, we have designed compounds which target onco-specific enzymes simultaneously – our goal is to starve cancer cells of their energy.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Moncton|Moncton, New Brunswick, Canada
Recipient Type
For-profit organization
Business Number
756525093
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-06-04 | 2018-19 | $35,440.00 |
| 1 | 2018-06-04 | 2018-19 | $50,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days. The total amended value is 14,560 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 92 jours. La valeur totale des modifications est de 14 560 dollars.
Agreement End Date
2018-12-31
Agreement Number
907704
Agreement Start Date
2018-06-04
Agreement Title
Cell Line Testing for Tumor Shrinkage
Agreement Title (French)
Testing de ligne cellulaire de tumeur en retrait
Agreement Type
Contribution
Agreement Value
$50,000.00
Amendment Date
2018-11-15
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Tieös Pharmaceuticals is a pre-clinical stage biotech company with the goal of creating novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells.
With the use of advanced AI-based computational biology and 3D in-silico models, we have developed lead polypharmocological compounds which will each target multiple metabolic pathways simultaneously; creating synergies and reducing toxicity. Through a proprietary weighting of cancer specific metabolic pathways, we have now synthesized our five lead compounds and are conducting proof-of-concept in-vitro testing.
At Tieös, we have designed compounds which target onco-specific enzymes simultaneously – our goal is to starve cancer cells of their energy.
Description (French)
Testing de ligne cellulaire de tumeur en retrait
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Moncton--Riverview--Dieppe
Federal Riding (French)
Moncton--Riverview--Dieppe
Federal Riding Number
13007
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
756525093
Recipient City
Moncton|Moncton
Recipient Country
CA
Recipient Legal Name
Tieos Pharmaceuticals Inc.
Recipient Postal Code
E1A 6N9
Recipient Province or Territory
NB
Recipient Type
F
Reference Number
172-2018-2019-Q1-907704
